Related Experiment Video
Updated: Jan 27, 2026

Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
Safety and immunogenicity of pneumococcal conjugate vaccines in preterm infants
Carolina López-Sanguos1,2, Irene Rivero Calle1,2, Carmen Rodriguez Tenreiro1,2
1a Translational Paediatrics and Infectious Diseases, Department of Paediatrics , Hospital Clínico Universitario de Santiago de Compostela , Santiago de Compostela , Spain.
Insights
Pneumococcal conjugate vaccines (PCVs) are safe and effective for preterm infants, including those with low birth weight. Hospitalized premature infants require 48-hour observation post-immunization due to potential apnea risks.
Area of Science:
- Pediatrics
- Immunology
- Vaccinology
Background:
- Invasive pneumococcal diseases (IPD) have decreased globally due to pneumococcal conjugate vaccines (PCVs).
- Preterm infants face higher risks of invasive bacterial infections and often experience delayed immunizations.
- Delayed PCV administration in preterm infants increases their susceptibility to severe infections.
Purpose of the Study:
- To review the immunogenicity and safety of PCVs in preterm infants.
- To assess the suitability of PCVs for low birth weight and hospitalized preterm populations.
Main Methods:
- Systematic review of published literature on PCV use in preterm infants.
- Analysis of immunogenicity and safety data, including local and systemic reactions.
- Evaluation of reported risks such as apnea.
Main Results:
- PCVs demonstrate safety and efficacy in low birth weight and hospitalized preterm infants.
- Local and systemic reactions in preterm infants are comparable to those in term infants.
- Inconsistent reports exist regarding the risk of apnea post-PCV administration.
Conclusions:
- PCVs are recommended for preterm infants, with similar safety profiles to term infants.
- Hospitalized extremely premature infants should be monitored for at least 48 hours after PCV immunization due to potential apnea risks.
Introduction:
The introduction of pneumococcal conjugate vaccines (PCVs) in the routine immunization program has resulted in a significant decline in invasive pneumococcal diseases (IPD) around the world. Preterm infants are a special group at a high risk of invasive infection by encapsulated bacteria. However, their slow growth accrual and prolonged hospital stay frequently lead to delays in immunization, which contributes to their risk for severe infections. Areas covered: Authors reviewed the published immunogenicity and safety of the use of PCVs in preterm infants. Expert opinion: PCVs are safe and effective for use in low birth weight and in-hospital preterm infants. Local and systemic reactions are similar for both term and preterm populations. Reports were inconsistent on the risk of apnea, therefore hospitalized extremely premature infants should be kept under observation for at least 48 h after immunization.
Related Concept Videos
Vaccinations
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Conjugated Proteins
Survey Safety
Conjugation
Mechanism of Conjugation

